Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

Esthesioneuroblastoma laboratory findings

Introduction

Overview

Overview

Laboratory findings consistent with the diagnosis of [disease name] include hypercalcemia, syndrome of inappropriate antidiuretic hormone (SIADH), hyponatremia, and neurological paraneoplastic syndromes.

Laboratory Findings

Laboratory Findings

Laboratory findings consistent with the diagnosis of esthesioneuroblastoma include the following:[1][2][3][4][5]

References

References

  1. ↑ Ward PD, Heth JA, Thompson BG, Marentette LJ (2009). “Esthesioneuroblastoma: Results and Outcomes of a Single Institution’s Experience”. Skull Base. 19 (2): 133–40. doi:10.1055/s-0028-1096195. PMC 2671304. PMID 19721769.
  2. ↑ Koo BK, An JH, Jeon KH, Choi SH, Cho YM, Jang HC; et al. (2008). “Two cases of ectopic adrenocorticotropic hormone syndrome with olfactory neuroblastoma and literature review”. Endocr J. 55 (3): 469–75. PMID 18469486.
  3. ↑ Sharma S, Lasheen W, Walsh D (2008). “Paraneoplastic refractory hypercalcemia due to advanced metastatic esthesioneuroblastoma”. Rhinology. 46 (2): 153–5. PMID 18575019.
  4. ↑ Gabbay U, Leider-Trejo L, Marshak G, Gabbay M, Fliss DM (2013). “A case and a series of published cases of esthesioneuroblastoma (ENB) in which long-standing paraneoplastic SIADH had preceded ENB diagnosis”. Ear Nose Throat J. 92 (10–11): E6. PMID 24170477.
  5. ↑ Kunc M, Gabrych A, Czapiewski P, Sworczak K (2015). “Paraneoplastic syndromes in olfactory neuroblastoma”. Contemp Oncol (Pozn). 19 (1): 6–16. doi:10.5114/wo.2015.46283. PMC 4507891. PMID 26199564.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Simrat Sarai, M.D. [2]